Related Experiment Video

Updated: Jan 24, 2026

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

15.2K

Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer

Monica Capozzi1, Chiara De Divitiis2, Alessandro Ottaiano3

  • 1Department of Abdominal Oncology, Istituto Nazionale Tumori, IRCCS - Fondazione "G. Pascale", Napoli, Italia.

Cancer Management and Research
|May 24, 2019
PubMed

Insights

Lenvatinib, a multi-kinase inhibitor, shows efficacy in treating cancers like renal cell carcinoma. Identifying biomarkers for lenvatinib efficacy and resistance is crucial for patient selection.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Lenvatinib is a multi-kinase inhibitor with anti-angiogenic properties.
  • It targets VEGFR, FGFR, PDGFRα, KIT, and RET signaling pathways.
  • Lenvatinib is approved for renal cell carcinoma, differentiated thyroid cancer, and hepatocellular carcinoma.

Purpose of the Study:

  • To review the development of lenvatinib from preclinical stages to clinical application.
  • To discuss the efficacy, toxicity, and future perspectives of lenvatinib treatment.

Main Methods:

  • Literature review using PubMed, MEDLINE, and clinicaltrials.gov.
  • Analysis of preclinical in vitro and in vivo data.
  • Evaluation of clinical efficacy and toxicity data.

Main Results:

  • Lenvatinib demonstrates efficacy in treating specific cancers.
  • Common side effects include hypertension, proteinuria, fatigue, and diarrhea, linked to angiogenesis inhibition.
  • Biomarker identification for efficacy and resistance is a significant challenge.

Conclusions:

  • Lenvatinib is a valuable therapeutic agent for certain cancers.
  • Managing side effects and identifying predictive biomarkers are key for optimizing lenvatinib use.
  • Further research is needed to expand its clinical applications and improve patient outcomes.
Keywords:
kinase inhibitorsangiogenesismicrovessel densitytumors

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.3K
Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens09:26

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens

Published on: July 29, 2011

17.0K

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.9K
The Evidence for Evolution02:55

The Evidence for Evolution

Genetic variations accumulating within populations over generations give rise to biological evolution. Evolutionary changes can result in the formation of novel varieties and entire new species. These changes are responsible for the diverse forms of life inhabiting the planet. The evidence for evolution suggests that all living organisms descended from common ancestors.
47.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
521
Molecules and Compounds02:38

Molecules and Compounds

Atoms and Molecules
68.4K
Sustainable Development01:43

Sustainable Development

As the human population continues to grow and use resources, we must be mindful of our planet’s natural limits. Sustainable development provides a pathway to maintain and improve human life now while also ensuring that future generations will have the resources that they need. The long-term success of sustainability efforts rests on understanding the interplay between human actions and ecological systems.
14.8K